Allarity Therapeutics Announces Shareholder Acceptance of Share Swap Offer and Initiates Delisting of the Company’s Shares from Nasdaq First North
11 déc. 2021 09h35 HE
|
Allarity Therapeutics A/S
Press release Hørsholm, Denmark (December 11, 2021) — Allarity Therapeutics A/S (“Allarity A/S” or the “Company”) today announced that in excess of 94 % of the Company’s shareholders...
Allarity Therapeutics A/S Publishes Offer Document Offering to Acquire Company Shares in Exchange for Shares in Allarity Therapeutics, Inc. with the Intent to Complete Recapitalization
24 nov. 2021 17h15 HE
|
Allarity Therapeutics A/S
Press release Hørsholm, Denmark (November 24, 2021) — Allarity Therapeutics A/S ("Allarity A/S" or the "Company") hereby announces a voluntary offer and offer document to the shareholders of...
Grant of New Warrants and Resolutions on Existing Warrants
24 nov. 2021 15h50 HE
|
Allarity Therapeutics A/S
Company Announcement Hørsholm, Denmark (November 24, 2021) — Allarity Therapeutics A/S ("Allarity" or the "Company") today announced that the Board of Directors of Allarity has exercised the...
Allarity Therapeutics Publishes Interim Report for the Period January – September 2021
23 nov. 2021 02h00 HE
|
Allarity Therapeutics A/S
Press Release Hørsholm, Denmark (November 23, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announces the publication of its Interim Report for the period January – September...
Minutes of Extraordinary General Meeting held on 22 November 2021
22 nov. 2021 18h00 HE
|
Allarity Therapeutics A/S
Company Announcement Minutes of Extraordinary General Meeting held on 22 November 2021The English part of this parallel document in Danish (attached) and English is an unofficial translation of the...
Allarity Therapeutics’ Oral PARP Inhibitor, Stenoparib, Demonstrates Pre-clinical Antiviral Activity Against Delta Variant of Coronavirus
11 nov. 2021 02h30 HE
|
Allarity Therapeutics A/S
Current positive results with delta variant B.1.617.2 follows previous pre-clinical tests, including testing of alpha variant B.1.1.7 (“British” variant),beta variant B.1351 (“South African” variant),...
NOTICE OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF ALLARITY THERAPEUTICS A/S TO BE HELD ON NOVEMBER 22, 2021
05 nov. 2021 17h11 HE
|
Allarity Therapeutics A/S
Press release THE BOARD OF DIRECTORS HEREBY CONVENES an extraordinary general meeting of the shareholders of Allarity Therapeutics A/S (“Allarity A/S”) to be held on November 22, 2021 at 10:00 am...
U.S. SEC Issues Order Declaring Allarity Therapeutics Inc.’s Form S-4 Registration Statement Effective Ahead of Planned Transition to U.S. Nasdaq
05 nov. 2021 16h48 HE
|
Allarity Therapeutics A/S
An application for listing on the U.S. Nasdaq Stock Market for the shares of Allarity Therapeutics, Inc. (Delaware) (Nasdaq: ALLR) has been made conditioned upon shareholder approval of the...
Allarity Therapeutics and Lonza Collaborate to Manufacture Dovitinib, a Renal Cell Carcinoma Candidate
23 sept. 2021 03h00 HE
|
Allarity Therapeutics A/S
Integrated solution for process development and manufacturing of drug substance and drug product will facilitate the advancement of clinical developmentThe agreement meets Allarity’s needs for...
Allarity Therapeutics Presents Dovitinib Survival Data from DRP® Screened RCC Patients at ESMO 2021 Virtual Congress
16 sept. 2021 04h00 HE
|
Allarity Therapeutics A/S
Patient selection using DRP® score of 50% resulted in a median survival of 15.0 monthPatient selection using DRP® score of 67% resulted in a median survival of 20.6 months Press Release Hørsholm,...